This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (50)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Patient Safety/ Medical Error  • Neoplasms  • Psoriasis  • Dermatologic Procedures  • Phototherapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Warwick L. Morison, MD; Richard D. Baughman, MD; Robert M. Day, PhD; P. Donald Forbes, PhD; Herbert Hoenigsmann, MD; Gerald G. Krueger, MD; Mark Lebwohl, MD; Robert Lew, PhD; Luigi Naldi, MD; John A. Parrish, MD; Michael Piepkorn, MD, PhD; Robert S. Stern, MD; Gerald D. Weinstein, MD; S. Elizabeth Whitmore, MD

Arch Dermatol. 1998;134:595-598.

The possibility that there is an increased risk of melanoma in patients with psoriasis treated with psoralen–UV-A (PUVA) therapy has raised concern on the part of physicians and patients about the long-term safety of this treatment. In response to this concern, the National Psoriasis Foundation sponsored a workshop at which invited participants with expertise in PUVA therapy, psoriasis treatment, melanoma and nonmelanoma skin cancer, and epidemiological and clinical trials were asked to develop a consensus on the following 3 issues: the risk of long-term adverse effects of PUVA therapy with emphasis on nonmelanoma and melanoma skin cancer; the guidelines for physicians and patients for selection and use of PUVA therapy with consideration of the risk-benefit ratio of this treatment compared with the risk-benefit ratios of alternative treatments; and the directions for further evaluation of the long-term effects of PUVA therapy.

From the Departments of Dermatology, Johns Hopkins University, Baltimore, Md (Drs Morison and Whitmore), Dartmouth-Hitchcock Medical Center, Lebanon, NH (Dr Baughman), the University of Utah, Salt Lake City (Dr Krueger), Mount Sinai Medical Center, New York, NY (Dr Lebwohl), Brigham and Women's Hospital (Dr Lew), Massachusetts General Hospital (Dr Parrish), and Beth Israel Deaconess Medical Center (Dr Stern), Boston, Mass, the University of Milan, Bergamo, Italy (Dr Naldi), the University of Washington, Seattle (Dr Piepkorn), and the University of California, Irvine (Dr Weinstein); Clinicor Inc, Austin, Tex (Dr Day); Argus Research Laboratories Inc, Horsham, Pa (Dr Forbes); and the Division of Special Dermatology, University of Vienna Medical School, Vienna, Austria (Dr Hoenigsmann).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psoriasis: advances in pathophysiology and management
MacDonald and Burden
Postgrad. Med. J. 2007;83:690-697.
ABSTRACT | FULL TEXT  

Chemoprevention of Cancer
Tsao et al.
CA Cancer J Clin 2004;54:150-180.
ABSTRACT | FULL TEXT  

The Risk of Malignancy Associated With Psoriasis
Margolis et al.
Arch Dermatol 2001;137:778-783.
ABSTRACT | FULL TEXT